Skip to main content
EJNMMI Research
Fig. 3 | EJNMMI Research

Fig. 3

From: Kinetic analysis of dominant intraprostatic lesion of prostate cancer using quantitative dynamic [18F]DCFPyL-PET: comparison to [18F]fluorocholine-PET

Fig. 3

PET/CT images of the same patients as Fig. 2 showing maximum intensity projection of [18F]FCH PET SUV map in an axial view superimposed on CT (a) and in a coronal view by itself (b); the same two views for a [18F]DCFPyL study on another patient are shown in (c) and (d). The colour bar shows the scale of SUV. Localization of DIL (yellow arrow) with PET in both patients agreed with pre-operative prostate sextant biopsy. [18F]DCFPyL SUV map shows superior tumour contrast relative to benign prostatic tissue and better localization of DIL than [18F]FCH. PET, positron emission tomography; CT, computed tomography; FCH, fluorocholine; SUV, standardized uptake value; DCFPyL, 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid; DIL, dominant intraprostatic lesion

Back to article page